Tislelizumab is BeiGene’s programmed cell death protein 1 (PD-1) checkpoint inhibitor and Anktiva is an interleukin-15 (IL-15) superagonist from ImmunityBio. The trial aims to confirm the safety and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback